Wade Wolowiec, DO
Psychiatry · Seven Fields, PANPI 1124553953
Payments from drug & device makers
Across 42 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$382
- Otsuka America Pharmaceutical, Inc.$106
- Takeda Pharmaceuticals U.S.A., Inc.$59
- Neos Therapeutics, LP$52
- Johnson & Johnson$39
- Sunovion Pharmaceuticals Inc.$32
- plus $97 from 5 others
What the payments were for
- Food & beverage$768100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $382 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Neos Therapeutics, LP | 3 | $52 |
| Johnson & Johnson | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 3 | $32 |
| Bausch Health US, LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $21 |
| Corium, LLC | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$768 in reported general payments places this provider in the 70th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 17 | $3,657 |
| Methylphenidate ErMethylphenidate Hcl | 32 | $3,479 |
| Duloxetine Hcl | 37 | $2,124 |
| Fluoxetine Hcl | 32 | $1,128 |
| Vilazodone Hcl | 14 | $862 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $861 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 33 | $594 |
| Buspirone Hcl | 49 | $479 |
| Lorazepam | 50 | $462 |
| Olanzapine | 15 | $445 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $437 |
| Bupropion XlBupropion Hcl | 17 | $407 |
| Quetiapine Fumarate | 23 | $405 |
| Aripiprazole | 28 | $404 |
| Trazodone Hcl | 37 | $292 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Seven Fields
- Michelle BarwellSeven Fields$22K
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.